4 April 2024
VENTURE LIFE GROUP
PLC
("Venture
Life", "VLG" or the "Group")
Notice of
Results
and
Investor Presentation via
Investor Meet Company
Venture Life Group plc (AIM: VLG), a
leader in developing, manufacturing and commercialising products
for the self-care market confirms that it will release its results
for the year ended 31 December 2023 on 9 April 2024.
The Company also announces that Jerry
Randall (CEO) and Daniel Wells (CFO) will provide a live
presentation relating to the 2023 Full Year Results via Investor
Meet Company on 11 Apr 2024, 14:30 BST.
The presentation is open to all
existing and potential shareholders. Questions can be submitted
pre-event via your Investor Meet Company dashboard up until 9:00am
the day before the meeting or at any time during the live
presentation.
Investors can sign up to Investor
Meet Company for free and add to meet Venture Life Group plc
via:
https://www.investormeetcompany.com/venture-life-group-plc/register-investor
Investors who already follow Venture
Life Group plc on the Investor Meet Company platform will
automatically be invited.
For
further information, please contact:
|
Venture Life Group PLC
|
+44 (0) 1344 578004
|
|
Jerry Randall, Chief Executive
Officer
Daniel Wells, Chief Financial
Officer
|
|
|
Cavendish Capital Markets Limited (Nomad and
Broker)
|
+44 (0) 20 7720 0500
|
|
Stephen Keys/Camilla
Hume (Corporate Finance)
Michael Johnson (Sales)
|
|
|
|
|
|
|
|
|
|
About Venture Life (www.venture-life.com)
Venture Life is an international
consumer self-care company focused on developing, manufacturing and
commercialising products for the global self-care market. With
operations in the UK, Italy, The
Netherlands and Sweden, the Group's product portfolio
includes some key products such as the Balance Active range in the
area of women's intimate healthcare, the Earol® product line in ENT
care, the Lift and Glucogel product ranges for energy and glucose
management and hypoglycaemia, the UltraDEX and Dentyl oral care
product ranges, products for fungal infections and proctology, and
dermo-cosmetics for addressing the signs of ageing. Its products
are sold in over 90 countries worldwide.
The products, which are typically
recommended by pharmacists or healthcare practitioners, are
available primarily through pharmacies and grocery multiples. In
the UK and The Netherlands these are supplied
direct by the company to retailers, elsewhere they are supplied by
the Group's international distribution partners.
Through its two Development &
Manufacturing operations in Italy and Sweden, the
Group also provides development and manufacturing services to
companies in the medical devices and cosmetic sectors.